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ABSTRACT: Objective- -The present study investigated the pharmacokinetics of a single subcutaneous dose of 
human menopausal gonadotropin (hMG) on serum follicle-stimulating hormone (FSH) and luteinizing hor­
mone (LH) concentrations. Subjects and Methods—Six healthy female volunteers, aged 20-40 years, with regu­
lar menstrual cycles and normal endocrine profiles, who were not receiving any hormonal medication, were 
treated with the gonadotropin-releasing-hormone agonist buserelin to suppress endogenous gonadotropin 
release. One volunteer dropped out during treatment. When the serum estradiol concentration had fallen to 
below 500 pmol/L, an injection of 150 IU hMG (HumegonR) was given subcutaneously. Immediately before 
injection and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 15, 20, 24, 48 and 96 hours after, blood samples were drawn for deter­
mination of FSH and LH concentrations. Results—The baseline FSH level was 2.8 IU/L, and peak concentra­
tion (6.8 IU/L) was reached 12 hours after hMG injection (median values). Exogenous LH could not be 
measured because of the presence of endogenous LH. Discussion—The pattern of serum FSH concentrations 
after a single injection of hMG was found to resemble that seen after intramuscular hMG administration, 
although the peak FSH value was reached somewhat later. Int J Fertil 40(6):307-310, 1995
KEY WORDS: human menopausal gonadotropins (hMG), subcutaneous administration, pharmacokinetics, 
FSH, LH, ovarian stimulation, recombinant hMG
INTRODUCTION
ONADOTROPIN PREPARATIONS, SUCH
as human menopausal gonadotropin (hMG), 
are usually administered via the intramus­
cular (i.m.) route. The recent development 
of gonadotropin preparations of high purity, especial­
ly recombinant human follicle-stimulating hormone 
(FSH), makes possible subcutaneous (s.c.) adminis­
tration. Compared with i.m. administration, s.c. 
injections are less painful, and self-administration 
by the patient is more feasible.
The most appropriate dosage interval for s.c. 
administration is not known, since information is 
sparse regarding the pharmacokinetics of exogenous 
FSH and luteinizing hormone (LH) after s.c. 
gonadotropin injection. We therefore decided to 
study the effect of a single s.c. hMG injection on
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FIG. 1. Median serum follicle-stimulating hormone (FSH) 
concentrations and 10th and 90th percentiles after a single 
subcutaneous injection of 150 IU human menopausal 
gonadotropin during pituitaiy suppression by buserelin, in 
five female volunteers.
serum FSH and LH concentrations in female volun­
teers. Since the presence of high levels of endoge­
nous FSH and LH complicates interpretation of the 
results, pituitary function was suppressed by admin­
istering the gonadotropin-releasing-hormone 
(GnRH) agonist buserelin.
MATERIALS AND METHODS
Six female volunteers participated in the study. The 
inclusion criteria were as follows: age 20-40 years, a 
regular menstrual cycle (between 24 and 35 days), a 
normal endocrine serum profile in the early follicu­
lar phase of the cycle (FSH concentration below 8 
IU/L, LH/FSH ratio less than 3, testosterone concen­
tration below 2.5 nmol/L, prolactin concentration 
below 750 mlU/L, and thyroxine concentration 
between 58 and 148 nmol/L) and no intake of hor­
monal medication, including oral contraceptives, for 
at least 3 months prior to the study. The median age 
of the five volunteers who completed the study was 
29 years (range 29-38 years) and the median body 
mass index was 20.4 kg/m2 (18.4-27.3 lcg/m1).
All the women were treated with the GnRH-ago- 
nist buserelin (SuprefactR nasal spray, Hoechst A.G., 
Frankfurt, Germany) at a dose of 300 pg three times 
a day, from day 21 of the previous menstrual cycle
LH (IU/L)
hours
FIG. 2. Median serum luteinizing hormone (LH) concen­
trations and 10th and 90th percentiles after a single subcu- 
taneous in jection  of 150 IU hum an m enopausal 
gonadotropin during pituitary suppression by buserelin, in 
five female volunteers.
onwards. On day 10 of the buserelin treatment, the 
serum 17(3-estradiol concentration was determined 
and then measured every three or four days until it 
was below 500 pmol/L, One volunteer dropped out 
during the buserelin treatment because of sinusitis 
and nasal bleeding. As soon as the estradiol concen­
tration was found to be below 500 pmol/L, a single 
subcutaneous injection of 150 IU HumegonR (NV 
Organon, Oss, The Netherlands) was given the next 
day at 8 a.m. and the buserelin treatment was con­
tinued. Two ampules of Humegon were diluted in
0.5 mL solvent and injected subcutaneously in the 
abdomen using a syringe injector (MonojectR, Sher­
wood Medical, St. Louis, USA). Each ampule con­
tains 75 IU FSH and 75 IU LH activity , as 
determined by in vivo bioassays. Due to inherent 
inaccuracy of bioassays, results of determinations 
are within 80-125% of stated activity. One batch of 
Humegon was used for the study.
Blood samples were collected, either by venipunc­
ture or via an intravenous cannula, immediately 
before injection and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 15, 
20, 24, 48 and 96 hours after. Buserelin administra­
tion was stopped after the last blood samples were 
taken. The samples were centrifuged within three 
hours after collection and serum was frozen at -20°C 
until assayed.
The serum estradiol concentration on the tenth
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day of buserelin treatment was determined by a 
time-resolved fluoroimmunoassay (DelfiaR, Wallac 
Oy, Turku, Finland). The limit of 500 pmol/L was 
chosen because of the low sensitivity of the assay in 
the range from 150 to 500 pmol/L. The estradiol 
concentration immediately before the hMG injec­
tion was measured retrospectively by a more sensi­
tive radioim m unoassay [1]. FSH and LH 
concentrations were determined in all serum sam­
ples by immunoradiometric assays (IRMAs), as pre­
viously described [2].
Statistical analysis was performed using the 
Wilcoxon signed-rank test.
RESULTS
The median estradiol concentration immediately 
before the hMG injection, as measured by radioim­
munoassay, was 88 pmol/L (range <75-390 pmol/L). 
The median values of the FSH and LH concentra­
tions and the 10th and 90th percentiles, before and 
after HumegonR injection, are shown in Figures 1 
and 2, respectively. The median FSH concentration 
before injection was 2.8 (10th percentile (pio) 1.4 
IU/L; 90th percentile (p9o) 4.9 IU/L). Median FSH 
concentrations started to increase within the first 
half-hour after injection and reached a maximum 
value of 6.8 IU/L (pio 4.7 IU/L; p90 7.0 IU/L) after 12 
hours (pio 10 hours; p 90 12 hours), the increase being 
statistically significant (P < .05). Serum LH concen­
trations remained at a low level throughout the 
study. A small increase in median LH concentra­
tions was seen in the first two hours after the 
Humegon injection, but there was great interindi­
vidual variation and the increase was not statistical­
ly significant.
The subcutaneous injections were well tolerated. 
Two patients experienced transient pain at the injec­
tion site, starting 7 and 10 hours after injection, 
respectively, and lasting for a few hours. In one of 
these two patients the injection site showed redness 
without swelling (diameter of red area 1 to 2 cm). 
The symptoms were not severe in either case.
DISCUSSION
Subcutaneous administration of 150 IU hMG leads 
to an increase in serum FSH concentrations, reach­
ing a peak approximately 12 hours after injection
and gradually decreasing thereafter. In a previous 
study of similar design, the effect of a single i.m. or
i.v. injection of 150 IU hMG on serum FSH and LH 
levels was described [3], The increase in serum FSH 
levels after i.m. injection of hMG showed a substan­
tially similar pattern to that following s.c. injection, 
although the peak concentration seemed to occur 
somewhat earlier (8 hours after i.m. injection as 
against 12 hours after s.c injection).
In a study by Le Cotonnec et al [4], serum FSH 
concentrations were determined in male subjects 
after single i.m. and s.c. injections of 150 IU highly 
purified urinary FSH (Metrodin HPR). These investi­
gators found similar patterns of FSH concentrations 
after s.c. and i.m. administration, with maximum 
concentrations occurring 13 and 18 hours after i.m. 
and s.c. injection, respectively. In a study by Saal et 
al [5], pharmacokinetic parameters were described 
after single s.c. and i.m. injections of human chori­
onic gonadotropin (hCG) in male subjects. Serum 
hCG concentrations reached a peak value 6 and 16 
hours after i.m. and s.c. injection, respectively, the 
half-lives being 31 ± 3 and 38 ± 3 hours. The authors 
concluded that diffusion of hCG into the circulation 
was slower after s.c. administration. These investi­
gations differed from ours as regards the groups stud­
ied (male instead of female subjects) and the 
preparations administered (highly purified FSH and 
hCG instead of hMG). Nevertheless, serum concen­
trations showed a slightly slower and more pro­
longed increase after s.c. administration than after
i.m. administration in all studies.
Serum LH concentrations were insufficiently sup­
pressed to enable measurement of exogenous LH. 
There was great interindividual variation in the 
serum LH profiles and no clear pattern could be 
seen.
In the present study, a single s.c. hMG injection 
was well tolerated by all subjects. Repeated s.c. 
injections with hMG might induce local skin reac­
tions, such as swelling, redness or induration, since 
the urine-derived hMG preparations are of low puri­
ty and contain a large number of non-gonadotropin 
proteins [6]. However, a recombinant human FSH 
preparation of very high purity has been developed 
recently [7]. In contrast to hMG, recombinant 
human FSH should be very suitable for daily s.c. 
administration.
Since the FSH profile after s.c. injection showed 
that serum concentrations remained adequate over a 
period of 24 hours, subcutaneous gonadotropin
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injections can presumably be given once daily. This 
assumption is supported by the findings of Howies 
et al [8], who treated in vitro fertilization patients 
with a highly purified urinary FSH preparation 
which was administered once daily subcutaneously. 
This treatment schedule was found to be effective in 
stimulating multiple follicular development. The 
injections were also well tolerated. A pharmacoki­
netic study now needs to be carried out to measure 
serum FSH concentrations after repeated s.c. 
gonadotropin injections.
It may be concluded from the results of the pre­
sent study that once-daily subcutaneous administra­
tion of gonadotropins induces adequate serum 
concentrations of FSH and LH.
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